KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Assets (2016 - 2025)

Travere Therapeutics' Current Assets history spans 14 years, with the latest figure at $437.6 million for Q4 2025.

  • For Q4 2025, Current Assets rose 5.01% year-over-year to $437.6 million; the TTM value through Dec 2025 reached $437.6 million, up 5.01%, while the annual FY2025 figure was $437.6 million, 5.01% up from the prior year.
  • Current Assets reached $437.6 million in Q4 2025 per TVTX's latest filing, up from $371.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $686.2 million in Q3 2023 to a low of $324.7 million in Q3 2024.
  • Average Current Assets over 5 years is $506.0 million, with a median of $538.4 million recorded in 2022.
  • Peak YoY movement for Current Assets: surged 42.01% in 2021, then tumbled 52.68% in 2024.
  • A 5-year view of Current Assets shows it stood at $582.8 million in 2021, then dropped by 16.54% to $486.4 million in 2022, then increased by 26.79% to $616.8 million in 2023, then tumbled by 32.44% to $416.7 million in 2024, then rose by 5.01% to $437.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Current Assets are $437.6 million (Q4 2025), $371.1 million (Q3 2025), and $379.6 million (Q2 2025).